Aldeyra Therapeutics Stock Surges on Key Regulatory Advancements

Shares of Aldeyra Therapeutics experienced a significant rally, climbing 2.92% to reach a price of $5.26. This upward movement is a direct response to a series of positive regulatory developments announced by the biotechnology firm.

Market experts at Jones Trading have substantially increased their price target for Aldeyra Therapeutics following the recent news. The new target is set at $9, a notable rise from the previous $6. This upward revision reflects growing confidence in the company’s valuation, which is closely tied to positive regulatory updates for its lead drug candidate, Reproxalap. The consensus among analysts points to a “Strong Buy” rating, with average price targets ranging from $9.50 to $9.67.

Beyond analyst sentiment, Aldeyra is advancing its clinical pipeline. A Phase 2/3 clinical trial for... Read more...